By: Benzinga
Isis Pharma Posts Positive Phase 1 Data on Three Drugs in Development to Treat Metabolic Disorders
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced today positive results from Phase 1 studies of three drugs, ISIS-PTP1B[Rx], ISIS-GCGR[Rx] and ISIS-GCCR[Rx], in development to treat metabolic disorders, including type 2 diabetes. In all three Phase 1 studies, the drugs were safe and well tolerated with early encouraging data that supports the unique mechanism of
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here